Point72 Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-279,525
| Closed | -$6.02M | – | 3774 |
|
|
2025
Q4 | $6.02M | Buy |
+279,525
| New | +$5.43M | 0.01% | 1704 |
|
|
2025
Q3 | – | Sell |
-202,815
| Closed | -$2.64M | – | 2310 |
|
|
2025
Q2 | $1.79M | Buy |
202,815
+97,730
| +93% | +$859K | ﹤0.01% | 1353 |
|
|
2025
Q1 | $823K | Buy |
+105,085
| New | +$880K | ﹤0.01% | 1494 |
|
|
2024
Q1 | – | Sell |
-285,816
| Closed | -$4.26M | – | 2169 |
|
|
2023
Q4 | $4.04M | Buy |
+285,816
| New | +$3.36M | 0.01% | 1003 |
|
|
2023
Q3 | – | Sell |
-676,260
| Closed | -$11.1M | – | 2462 |
|
|
2023
Q2 | $11.1M | Buy |
676,260
+220,260
| +48% | +$2.86M | 0.03% | 556 |
|
|
2023
Q1 | $4.18M | Buy |
456,000
+179,034
| +65% | +$1.47M | 0.01% | 815 |
|
|
2022
Q4 | $1.98M | Buy |
+276,966
| New | +$1.94M | 0.01% | 935 |
|
|
2016
Q3 | – | Sell |
-461,839
| Closed | -$4.96M | – | 705 |
|
|
2016
Q2 | $4.96M | Buy |
461,839
+102,881
| +29% | +$1.1M | 0.03% | 428 |
|
|
2016
Q1 | $3.96M | Buy |
358,958
+291,946
| +436% | +$2.9M | 0.03% | 464 |
|
|
2015
Q4 | $818K | Buy |
+67,012
| New | +$1.04M | 0.01% | 620 |
|
|
2015
Q2 | – | Sell |
-355,800
| Closed | -$6.4M | – | 717 |
|
|
2015
Q1 | $6.4M | Buy |
+355,800
| New | +$5.57M | 0.04% | 401 |
|
Other funds holding AVDL
Point72 Asset Management's AVDL Position: Q1 2026 in Review
Point72 Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 279,525 shares — an estimated $6.02M sold.
Point72 Asset Management first reported a position in AVDL in Q1 2015 and held it in 11 quarters. The position peaked at $11.1M in Q2 2023. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Point72 Asset Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Point72 Asset Management sold 279,525 Avadel Pharmaceuticals shares in Q1 2026, an estimated $6.02M.
- Point72 Asset Management first reported a position in Avadel Pharmaceuticals in Q1 2015 and held it in 11 quarters.
- Point72 Asset Management's Avadel Pharmaceuticals position peaked at $11.1M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.